LAG-3-Ig fusion protein eftilagimod alpha plus pembrolizumab caused an overall response rate (ORR) of 33% and 50% in pembrolizumab-refractory and anti-PD-1 naïve non-small cell lung cancer (NSCLC) patients, respectively,53 and showed a similarly considerable effect54 in head and neck squamous cell carcinoma (HNSCC) patients, thus was granted fast track status by FDA for NSCLC and HNSCC. This evidence concerns the gene LAG3 and head and neck squamous cell carcinoma.